tenaxthera.com (TENX) - Earnings per share increase in current year

Tenax Therapeutics utilizes laboratories in North Carolina, outsourcing drug production to external CDMO bio-factories to minimize risks. Monitoring the chart on GURU.Markets, we note that the chart level of annual EPS growth is linked to a focus on clinical trials without current revenue, where the -3.70 level is the current value. Funding for pulmonary hypertension research relies on the gradual depletion of existing cash reserves.
Analytical breakdowns and data insights for company Tenax Therapeutics, Inc. (TENX)

This indicator tracks the year-over-year growth rate of earnings per share. It enables an assessment of business capitalization efficiency by identifying the risk of capital being frozen in a loss-making asset. By analyzing year-over-year EPS growth percentages, an investor can discern the impact of development costs for cardiovascular drugs. This metric's trend confirms the ability of Tenax Therapeutics (TENX) to monetize niche medications. Steady growth in this figure indicates the company's financial stability.